ReviewJournal of cellular and molecular medicine2019
Trabecular meshwork cells are a valuable resource for cellular therapy of glaucoma.
Review in Journal of cellular and molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Modeling of Lowe Patient-Derived Induced Pluripotent Stem Cells Into Trabecular Meshwork.American journal of ophthalmology · 2026Article
- Tackling visual impairment: emerging avenues in ophthalmology.Frontiers in medicine · 2025Review
- mTOR Inhibitors Modulate the Biological Nature of TGF-β2-Treated or -Untreated Human Trabecular Meshwork Cells in Different Manners.Biomedicines · 2024Article
- Glaucoma: Current and New Therapeutic Approaches.Biomedicines · 2024Review
- Development of Cell Culture Platforms for Study of Trabecular Meshwork Cells and Glaucoma Development.Tissue engineering and regenerative medicine · 2024Review
- Long non-coding RNA SNHG11 regulates the Wnt/β-catenin signaling pathway through rho/ROCK in trabecular meshwork cells.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023Article
- All-International journal of molecular sciences · 2022Article
- Newer advances in medical management of glaucoma.Indian journal of ophthalmology · 2022Review
- Normal and glaucomatous outflow regulation.Progress in retinal and eye research · 2021Review
- Suppression of TGF-β1 signaling by Matrigel via FAK signaling in cultured human trabecular meshwork cells.Scientific reports · 2021Article
- Trabecular meshwork cells are a valuable resource for cellular therapy of glaucoma.Journal of cellular and molecular medicine · 2019Review
- Human Trabecular Meshwork Progenitors.International journal of medical sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trabecular meshwork (TM) contains a subset of adult stem cells or progenitors that can be differentiated into corneal endothelial cells, adipocytes and chondrocytes, but not osteocytes or keratocytes. Accordingly, these progenitors can be utilized as a cell-based therapy to prevent blindness caused by glaucoma, corneal endothelial dysfunction and other diseases in general. In this review, we review in vitro expansion techniques for TM progenitors, discuss their phenotypic properties, and highlight their potential clinical applications in various ophthalmic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.